These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 9041428

  • 21. Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line.
    Pirounaki M, Heyden NA, Arens M, Ratner L.
    J Virol Methods; 2000 Mar; 85(1-2):151-61. PubMed ID: 10716348
    [Abstract] [Full Text] [Related]

  • 22. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
    Pellegrin I, Segondy M, Garrigue I, Izopet J, Montes B, Pellegrin JL, Reynes J, Massip P, Puel J, Fleury H.
    J Acquir Immune Defic Syndr; 2000 Dec 15; 25(5):465-6. PubMed ID: 11141248
    [No Abstract] [Full Text] [Related]

  • 23. In-vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response.
    Edlin BR, St Clair MH, Pitha PM, Whaling SM, King DM, Bitran JD, Weinstein RA.
    Ann Intern Med; 1992 Sep 15; 117(6):457-60. PubMed ID: 1503348
    [Abstract] [Full Text] [Related]

  • 24. Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines.
    Kageyama S, Amolong Hinay A, Telan EFO, Samonte GMJ, Leano PSA, Tsuneki-Tokunaga A, Kanai K.
    J Int Assoc Provid AIDS Care; 2019 Sep 15; 18():2325958219856579. PubMed ID: 31216920
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Drug-antibody conjugates with anti-HIV activity.
    Paulik M, Grieco P, Kim C, Maxeiner HG, Grunert HP, Zeichhardt H, Morré DM, Morré DJ.
    Biochem Pharmacol; 1999 Dec 01; 58(11):1781-90. PubMed ID: 10571253
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH.
    J Virol; 1996 Sep 01; 70(9):5922-9. PubMed ID: 8709213
    [Abstract] [Full Text] [Related]

  • 32. [Combination of phosphazide and crixivan inhibit replication of HIV-1 strains that are resistant to azidothymidine].
    Selimova LM, Kraevskiĭ AA, Galegov GA.
    Dokl Akad Nauk; 1999 Dec 01; 369(6):847-9. PubMed ID: 10687056
    [No Abstract] [Full Text] [Related]

  • 33. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
    Duan C, Poticha D, Stoeckli TC, Petropoulos CJ, Whitcomb JM, McHenry CS, Kuritzkes DR.
    J Infect Dis; 2001 Nov 15; 184(10):1336-40. PubMed ID: 11679926
    [Abstract] [Full Text] [Related]

  • 34. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
    Kollmann C, Tremblay C, Giguel F, Chou TC, Hirsch MS.
    Antivir Ther; 2001 Jun 15; 6(2):143-4. PubMed ID: 11491419
    [No Abstract] [Full Text] [Related]

  • 35. [Recombinant virus assay: a rapid assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates].
    Qin SL, Arendt V, Hemmer R, Schneider F, Wang AX, Sheng RY.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Oct 15; 24(5):523-6. PubMed ID: 12905778
    [Abstract] [Full Text] [Related]

  • 36. HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
    Rey D, Hughes M, Pi JT, Winters M, Merigan TC, Katzenstein DA.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar 01; 17(3):203-8. PubMed ID: 9495218
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.
    Antivir Chem Chemother; 2000 Jul 01; 11(4):291-301. PubMed ID: 10950391
    [Abstract] [Full Text] [Related]

  • 39. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.
    Harrigan PR, Bloor S, Larder BA.
    J Virol; 1998 May 01; 72(5):3773-8. PubMed ID: 9557659
    [Abstract] [Full Text] [Related]

  • 40. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
    Johnson VA, Merrill DP, Chou TC, Hirsch MS.
    J Infect Dis; 1992 Nov 01; 166(5):1143-6. PubMed ID: 1328402
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.